Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice

Life Sciences

Volumn 80, Issue 7, 2007, Pages 659-664

  Júnior, Álvaro D C ^a,b   Mota, Luciene G ^a   Nunan, Elzíria A ^a   Wainstein, Alberto J A ^a,c   Wainstein, Ana Paula D L ^a,c   Leal, Alexandre S ^d   Cardoso, Valbert N ^a   De Oliveira, Mônica C ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSIDADE FEDERAL DOS VALES DO JEQUITINHONHA E MUCURI   (Brazil)

^c Biocancer SA   (Brazil)

^d CENTRO DE DESENVOLVIMENTO DA TECNOLOGIA NUCLEAR   (Brazil)

Author keywords

Cisplatin; Stealth pH sensitive liposomes; Tissue distribution

Indexed keywords

CISPLATIN; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RETENTION; DRUG STABILITY; EHRLICH ASCITES TUMOR; ENCAPSULATION; FEMALE; ISOTOPE LABELING; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY TUBULE ABSORPTION; LIPOSOMAL DELIVERY; LIVER; MONOTHERAPY; MOUSE; NONHUMAN; PH; SPLEEN; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA, EHRLICH TUMOR; CISPLATIN; FEMALE; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; LIPOSOMES; MICE; TISSUE DISTRIBUTION;

MUS;

EID: 33846120629     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.10.011     Document Type: Article

References (19)

1. Bandak S., Horowitz D., Horowitz A., Tzemach D., and Gabizon A. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 10 (1999) 911-920
2. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nature Reviews Cancer 5 (2005) 161-171
3. Guillot T., Spielmann M., Kac J., Luboinski B., Tellez-Bernal E., Munck J.N., Bachouchi M., Armand J.P., and Cvitkovic E. Neoadjuvant chemotherapy in multiple synchronous head and neck and esophagus squamous cell carcinomas. Laryngoscope 102 (1992) 311-319
4. Harrington K.J., Lewanski C.R., and Stewart J.S.W. Liposomes as vehicles for targeted therapy of cancer. Part 1: preclinical development. Clinical Oncology 12 (2000) 2-15
5. Harrington K.J., Lewanski C.R., and Stewart J.S.W. Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development. Clinical Oncology 12 (2000) 16-24
6. Harrington K.J., Lewanski C.R., Northcote A.D., Whittaker J., Wellbank H., Vile R.G., Peters A.M., and Stewart J.S.W. Phase I-II study of pegylated liposomal cisplatin (SPI-077™) in patients with inoperable head and neck cancer. Annals of Oncology 12 (2001) 493-496
7. Hospers G.A., Mulder N.H., de Jong B., de Ley L., Uges D.R., Fichtinger-Schepman A.M., Scheper R.J., and de Vries E.G. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum (II) in vitro. Cancer Research 48 (1988) 6803-6807
8. Kondagunta G.V., Bacik J., Donadio A., Bajorin D., Marion S., Sheinfeld J., Bosl G.J., and Motzer R.J. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. Journal of Clinical Oncology 23 (2005) 6549-6555
9. Le Chevalier T., Brisgand D., and Doulliard J.Y. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. Journal of Clinical Oncology 12 (1994) 360-367
10. Leal A.S., Carvalho Júnior A.D., Abrantes F.M., Menezes M.A.B.C., Ferraz V., Cruz T.S., Cardoso V.N., and De Oliveira M.C. Production of the radioactive antitumoral cisplatin. Applied Radiation and Isotopes 64 (2005) 178-181
11. McIntosh D.P., Cooke R.J., McLachlan A.J., Daley-Yates P.T., and Rowland M. Pharmacokinetics and tissue distribution of cisplatin and conjugates of cisplatin with carboxymethyldextran and A5B7 monoclonal antibody in CD1 mice. Journal of Pharmaceutical Sciences 86 (1997) 1478-1483
12. Muggia F.M., and Fojo T. Platinums: extending their therapeutic spectrum. Journal of Chemotherapy 16 (2004) 77-82
13. Muggia F.M., and Los G. Platinum resistance: laboratory findings and clinical implications. Stem Cells 11 (1993) 182-193
14. Newman M.S., Colbern G.T., Working P.K., Engbers C., and Amantea M.A. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemotherapy and Pharmacology 43 (1999) 1-7
15. Shirazi F.H., Molepo J.M., Stewart D.J., Raaphorst G.P., and Goel R. Cytotoxicity, accumulation, and efflux of cisplatin and its metabolites in human ovarian carcinoma cells. Toxicology and Applied Pharmacology 140 (1996) 211-218
16. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
17. Steerenberg P.A., Storm G., de Groot G., Claessea A., Bergers J.J., Franken M.A.M., van Hoesel Q.G.C.M., Wubs K.L., and de Jong W.H. Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). Cancer Chemotherapy and Pharmacology 21 (1988) 299-307
18. Wang S., Mi J.-B., Li Y.-Z., Chang W.-B., and Ci Y.-X. Pharmacokinetics and tissue distribution of iv injection of polyphase liposome-encapsulated cisplatin (KM-1) in rats. Acta Pharmacologica Sinica 24 (2003) 589-592
19. Wernyj R.P., and Morin P.J. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updates 7 (2004) 227-232